Alan M. Mendelsohn, MD, Chief Medical Officer at Timber Pharmaceuticals, provides an overview of congenital ichthyosis.
As Dr. Mendelsohn explains, congenital ichthyosis is a rare genetic skin disorder. It is characterized by dry, thickened, and scaling skin. Individuals with this condition may experience a limited range of motion, chronic itching, an inability to sweat, and an increased risk of infections.
Currently, Timber Pharmaceuticals is focusing on two subtypes of this rare disease: the x-linked form which is more common in males than females, and autosomal recessive congenital (also known as lamellar) ichthyosis. The latter is rarer overall. The company recently presented 7 abstracts at the 31st European Academy of Dermatology and Venereology Congress detailing positive clinical data from the completed phase 2b CONTROL study of TMB-001. TMB-001 is a topical isotretinoin that is currently under investigation for treatment.
To learn more about congenital ichthyosis and other rare skin disorders, visit https://checkrare.com/diseases/skin-conditions/
